Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer

Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab.

(2017) D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Dinutuximab: First Global Approval

(2015) Sohita Dhillon   DRUGS

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours

(2015) Steven Mo et al.   JOURNAL OF CONTROLLED RELEASE

Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model

(2015) T. Roy Chaudhuri et al.   MOLECULAR CANCER THERAPEUTICS

ImmTACs for targeted cancer therapy: Why, what, how, and which

(2015) Joanne Oates et al.   MOLECULAR IMMUNOLOGY

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

(2015) Laura Evgin et al.   MOLECULAR THERAPY

First oncolytic virus edges towards approval in surprise vote

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

(2015) Tao Dao et al.   NATURE BIOTECHNOLOGY

Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma

(2015) Mark Middleton et al.   CANCER RESEARCH

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells

(2014) Giovanna Bossi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Daratumumab granted breakthrough drug status

(2014) Jacob P Laubach et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

EPR: Evidence and fallacy

(2014) Joseph W. Nichols et al.   JOURNAL OF CONTROLLED RELEASE

State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines

(2014) Charlene M. Dawidczyk et al.   JOURNAL OF CONTROLLED RELEASE

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Bispecific antibodies rise again

(2014) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

(2014) J. E. Zuckerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

(2014) Lidia Robert et al.   OncoImmunology

Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy

(2014) Amber Miller et al.   Molecular Therapy-Oncolytics

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

Combining virotherapy and angiotherapy for the treatment of breast cancer

(2013) M Bazan-Peregrino et al.   CANCER GENE THERAPY

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

(2013) U. Prabhakar et al.   CANCER RESEARCH

Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy

(2013) C. J. Nirschl et al.   CLINICAL CANCER RESEARCH

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes

(2013) Susan M. Graham et al.   JOURNAL OF CONTROLLED RELEASE

Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound

(2013) Robert Carlisle et al.   JNCI-Journal of the National Cancer Institute

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement

(2013) Zhili Xu et al.   NATURE MEDICINE

New viruses for cancer therapy: meeting clinical needs

(2013) Tanner S. Miest et al.   NATURE REVIEWS MICROBIOLOGY

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

(2012) Hiroshi Maeda et al.   ADVANCED DRUG DELIVERY REVIEWS

Liposomal drug delivery systems: From concept to clinical applications

(2012) Theresa M. Allen et al.   ADVANCED DRUG DELIVERY REVIEWS

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

(2012) Emmet McCormack et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

(2012) R. A. de Claro et al.   CLINICAL CANCER RESEARCH

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

(2012) D. G. Branstetter et al.   CLINICAL CANCER RESEARCH

Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies

(2012) Milos Aleksic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Monoclonal TCR-redirected tumor cell killing

(2012) Nathaniel Liddy et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Tumor Vascular Priming by a Nanoparticulate Doxorubicin Formulation

(2012) Tista Roy Chaudhuri et al.   PHARMACEUTICAL RESEARCH

Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation

(2012) Robert Carlisle et al.   PHARMACEUTICAL RESEARCH

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

(2011) Maite Verreault et al.   BMC CANCER

Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization

(2011) E. J. Ilett et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

(2011) J D Dias et al.   GENE THERAPY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

(2011) Twan Lammers et al.   JOURNAL OF CONTROLLED RELEASE

Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis

(2011) Tanner S Miest et al.   MOLECULAR THERAPY

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

(2010) Carol M Lee et al.   BMC CANCER

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study

(2010) J García-Castro et al.   CANCER GENE THERAPY

Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

(2010) J. D. Dias et al.   CLINICAL CANCER RESEARCH

Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

(2010) M. J. Besser et al.   CLINICAL CANCER RESEARCH

Ramucirumab (IMC-1121B): a novel attack on angiogenesis

(2010) Jennifer L Spratlin et al.   Future Oncology

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood

(2010) A Danielsson et al.   GENE THERAPY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

(2010) David Thomas et al.   LANCET ONCOLOGY

Catumaxomab

(2010) Rolf Linke et al.   mAbs

Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers

(2010) Chunsheng Liu et al.   MOLECULAR THERAPY

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

(2010) Sonia Guedan et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelial–epithelial Syncytia

(2010) Hannah H Chen et al.   MOLECULAR THERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1

(2009) R. C. Carlisle et al.   BLOOD

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

(2009) R. J. Prestwich et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

(2009) E J Ilett et al.   GENE THERAPY

The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

(2009) Robin J. Prestwich et al.   HUMAN GENE THERAPY

Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus

(2009) Konstantin Doronin et al.   HUMAN GENE THERAPY

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy

(2009) Candice Willmon et al.   MOLECULAR THERAPY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells

(2009) Ryan Cawood et al.   PLoS Pathogens

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

(2008) Simon N. Waddington et al.   CELL

Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts

(2008) J. H.E. Baker et al.   CLINICAL CANCER RESEARCH

Factors influencing retention of adenovirus within tumours following direct intratumoural injection

(2008) M Bazan-Peregrino et al.   GENE THERAPY

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

(2008) C L White et al.   GENE THERAPY

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

(2008) A T Power et al.   GENE THERAPY

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

(2008) J Qiao et al.   GENE THERAPY

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer

(2008) A. L. Parker et al.   JOURNAL OF VIROLOGY

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH

Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model

(2008) Maria A Thomas et al.   MOLECULAR THERAPY

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

(2008) Roberto Cattaneo et al.   NATURE REVIEWS MICROBIOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD